Development of an efficient expansion protocol for human CD4- iNKT

Overview
This conference poster tested four cytokines for expanding human CD4-negative invariant NKT (iNKT) cells from healthy donor blood, and IL-15 given on day 0 worked best. Culture in a G-Rex® bioreactor gave greater iNKT expansion than expansion bags by day 14, and the cells killed the THP-1 leukemia line.
What this paper found
Combining IL-15 with the G-Rex® bioreactor gives an efficient way to expand human CD4-negative invariant NKT cells from healthy donor blood. PBMC were cultured for 14 days with α-GalCer and one of IL-2, IL-4, IL-7 or IL-15; IL-15 added at day 0 produced the strongest expansion of total and subset-specific iNKT cells. G-Rex® cultures outperformed expansion bags at day 14 and raised the CD4-negative fraction, which stayed stable in bags. Expanded cells produced IFN-γ and IL-4, retained perforin and granzyme B, killed THP-1 leukemia cells and induced apoptosis in allogeneic dendritic cells. In irradiated NSG mice given human PBMC, co-transfer of expanded iNKT cells improved survival (p = 0.0140).
Note: Preclinical study using healthy donor cells in vitro and a xenogeneic GVHD mouse model; presented as a conference poster.
Simple, reproducible, and clinically GMP-ready protocol to efficiently expand iNKT cells from human blood. — Jordan Brouard, Cristina Caraiman, Tereza Coman, Marie-Thérèse Rubio
Study details
- Authors
- Jordan Brouard, Cristina Caraiman, Tereza Coman, Marie-Thérèse Rubio
- Institution
- Université de Lorraine, CNRS, IMoPA, Nancy, France · Hematology department, Nancy university hospital, Nancy, France · Hematology department, Institut Gustave Roussy, Villejuif, France
- Year
- 2025
- Cell type(s)
- NKT Cells
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
How G-Rex® was used
Human PBMC isolated from healthy donor blood by Lymphosep separation were cultured in a G-Rex® bioreactor with IL-15 and α-GalCer for 14 days, and compared with culture in an expansion bag under the same conditions. The cells were then sorted for iNKT and tested for function in vitro and in vivo. G-Rex® gave superior total and CD4-negative iNKT expansion at day 14 (G-Rex® n=14, bag n=8), and the CD4-negative percentage rose significantly in G-Rex® while remaining stable in bags.
Explore related
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.